Malignant Intracranial High Grade Glioma and Current Treatment Strategy

Author(s): Xiang Zhang*, Wei Zhang, Xing-Gang Mao, Wei-Dong Cao, Hai-Ning Zhen, Shi-Jie Hu.

Journal Name: Current Cancer Drug Targets

Volume 19 , Issue 2 , 2019

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Malignant high-grade glioma (HGG) is the most common and extremely fatal type of primary intracranial tumor. These tumors recurred within 2 to 3 cm of the primary region of tumor resection in the majority of cases. Furthermore, the blood-brain barrier significantly limited the access of many systemically administered chemotherapeutics to the tumor, pointing towards a stringent need for new therapeutic patterns. Therefore, targeting therapy using local drug delivery for HGG becomes a priority for the development of novel therapeutic strategies. The main objectives to the effective use of chemotherapy for HGG include the drug delivery to the tumor region and the infusion of chemotherapeutic agents into the vascular supply of a tumor directly, which could improve the pharmacokinetic profile by enhancing drug delivery to the neoplasm tissue. Herein, we reviewed clinical and molecular features, different methods of chemotherapy application in HGGs, especially the existing and promising targeting therapies using local drug delivery for HGG which could effectively inhibit tumor invasion, proliferation and recurrence of HGG to combat the deadly disease. Undoubtedly, novel chemical medicines targeting these HGG may represent one of the most important directions in the Neuro-oncology.

Keywords: Glioma, drug delivery, blood-brain barrier, Genetic alterations, chemotherapy, malignant high-grade glioma.

Rights & PermissionsPrintExport Cite as


Article Details

VOLUME: 19
ISSUE: 2
Year: 2019
Page: [101 - 108]
Pages: 8
DOI: 10.2174/1568009618666180530090922
Price: $58

Article Metrics

PDF: 17